B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
1 Year Est. Return
+46.72%
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Holding
104
Top Buys
| 1 | +$56.7M | |
| 2 | +$50.2M | |
| 3 | +$43.9M | |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| 1 | +$82.6M | |
| 2 | +$59.5M | |
| 3 | +$50.2M | |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| 1 | Healthcare | 87.27% |
| 2 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
1
Caris Life Sciences
CAI
$4.73B
| $143M | 4.78% |
8,009,447
+193,305
|
|
||
2
Neurocrine Biosciences
NBIX
$15.9B
| $85.9M | 2.87% |
652,121
-99,413
|
|
||
3
Glaukos
GKOS
$6.07B
| $82.2M | 2.74% |
763,505
-158,474
|
|
||
|
CNTA
4
Centessa Pharmaceuticals
CNTA
$6.15B
| $78.9M | 2.63% |
1,986,768
-201,552
|
|
||
5
Xenon Pharmaceuticals
XENE
$5.29B
| $77.8M | 2.6% |
1,338,452
-486,624
|
|
||
6
Dianthus Therapeutics
DNTH
$5.08B
| $75.5M | 2.52% |
899,364
-374,571
|
|
||
7
Edgewise Therapeutics
EWTX
$3.68B
| $73.9M | 2.47% |
2,347,583
-2,863,248
|
|
||
8
iRhythm Holdings
IRTC
$3.74B
| $72M | 2.4% |
610,192
+392,847
|
|
||
9
Nuvalent
NUVL
$8.72B
| $71.8M | 2.39% |
700,429
-120,977
|
|
||
10
Kodiak Sciences
KOD
$2.3B
| $69.3M | 2.31% |
1,818,665
-254,123
|
|
||
11
CG Oncology
CGON
$5.49B
| $66.7M | 2.22% |
984,783
-885,788
|
|
||
|
12
argenx
ARGX
$52B
| $62M | 2.07% |
84,939
+53,932
|
|
||
|
HNGE
13
Hinge Health
HNGE
$4.35B
| $56.1M | 1.87% |
1,455,123
+150,500
|
|
||
14
Acadia Pharmaceuticals
ACAD
$3.71B
| $55M | 1.84% |
2,471,199
+439,178
|
|
||
|
15
Monte Rosa Therapeutics
GLUE
$1.67B
| $52.7M | 1.76% |
3,206,574
+2,258,258
|
|
||
16
Krystal Biotech
KRYS
$9.11B
| $47.1M | 1.57% |
182,425
-19,676
|
|
||
17
Spyre Therapeutics
SYRE
$6.38B
| $47.1M | 1.57% |
932,823
-701,792
|
|
||
18
Guardant Health
GH
$17.2B
| $46.2M | 1.54% |
+499,712
|
|
||
19
Thermo Fisher Scientific
TMO
$183B
| $45.7M | 1.52% |
92,915
+12,190
|
|
||
|
GENB
20
Generate Biomedicines
GENB
$1.68B
| $44.9M | 1.5% |
+3,592,999
|
|
||
|
MBX
21
MBX Biosciences
MBX
$1.5B
| $44.6M | 1.49% |
1,492,467
+473,867
|
|
||
22
BrightSpring Health Services
BTSG
$12B
| $43.3M | 1.44% |
1,016,562
-179,224
|
|
||
23
Celldex Therapeutics
CLDX
$2.47B
| $43M | 1.43% |
1,356,082
-502,027
|
|
||
24
NeoGenomics
NEO
$1.37B
| $41.7M | 1.39% |
5,617,402
+984,601
|
|
||
25
Apogee Therapeutics
APGE
$6.19B
| $40.3M | 1.34% |
478,667
-96,400
|
|